Stocks
Fate Therapeutics (FATE) EBITDA margin US GAAP (year values) |
|||||||||
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | LTM ? | CAGR 5 years ? | |||
| EBITDA margin, % | ? | -378.1% | -305.9% | -271.1% | -1 295% | -1 911% | -1 925% | ||
| Changes by years, y/y, % | +20pp | +72pp | +35pp | -1 024pp | -616pp | +36.9% | |||
Fate Therapeutics. EBITDA margin, %
Fate Therapeutics. EBITDA margin, changes, pp
Fate Therapeutics (FATE) EBITDA margin US GAAP (quarter values) |
||||||||
| FY2025Q1 | FY2025Q2 | FY2025Q3 | FY2025Q4 | FY2026Q1 | LTM ? | |||
| EBITDA margin, % | ? | -2 329% | -1 615% | -1 667% | -2 141% | -2 178% | -1 925% | |
| Changes by years, y/y, % | +73pp | -1 019pp | -113pp | +128pp | +151pp | |||
| Changes by quarters, q/q, % | -61pp | +715pp | -52pp | -474pp | -37pp | |||
